Research
Hormonal
n-3 LC-PUFA reduce liver steatosis and hepatic glucose output by activating PPAR-alpha to stimulate fatty acid oxidation and suppressing SREBP-1c to inhibit lipogenesis enzymes.
For individuals with fatty liver, n-3 fatty acids may help reduce liver fat by shifting the liver's metabolism to burn fat (via PPAR-alpha) and stop making new fat (via SREBP-1c suppression).
GoodSupportsHIGH confidence
n-3 LC-PUFA stimulate fatty acid oxidation in the liver (via the activation of peroxisome proliferator activated receptor α (PPAR-α))... n-3 LC-PUFA inhibit both the activity and expression of liver glucose-6-phosphatase
Why this rating
Strong mechanistic evidence from rodent studies and molecular biology; human translation for NASH is suggested but less definitive.
Source
n-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?
Jacques Delarue et al. · annales de biologie animale biochimie biophysique · 2004
DOI 10.1051/rnd:2004033
narrative_reviewCited 207×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →